From AbbVie’s upadacitinib to new gene therapies: Pharma’s 2019 blockbuster launches, ranked
The biopharma industry will see seven blockbuster launches this year, according to Clarivate’s annual “Drugs to Watch” list for 2019! See how they rank:
- AbbVie’s upadacitinib
- Novartis’ Zolgensma
- AstraZeneca & FibroGen’s roxadustat
- Alexion’s Ultomiris
- Boehringer Ingelheim & AbbVie’s Skyrizi
- Aimmune’s AR-101
- bluebird bio’s LentiGlobin
